VGI Health Technology (XNEC:VTL) Dividend Payout Ratio : 0.00 (As of . 20)

View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Dividend Payout Ratio?

VGI Health Technology's dividend payout ratio for the months ended in . 20 was 0.00.

The historical rank and industry rank for VGI Health Technology's Dividend Payout Ratio or its related term are showing as below:

XNEC:VTL's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.435
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-28), the Dividend Yield % of VGI Health Technology is 0.00%.

VGI Health Technology's Dividends per Share for the months ended in . 20 was A$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

VGI Health Technology Dividend Payout Ratio Historical Data

The historical data trend for VGI Health Technology's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Dividend Payout Ratio Chart

VGI Health Technology Annual Data

Trend

Dividend Payout Ratio

VGI Health Technology Semi-Annual Data

Dividend Payout Ratio

Competitive Comparison of VGI Health Technology's Dividend Payout Ratio

For the Biotechnology subindustry, VGI Health Technology's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VGI Health Technology's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VGI Health Technology's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where VGI Health Technology's Dividend Payout Ratio falls into.

VGI Health Technology Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

VGI Health Technology's Dividend Payout Ratio for the fiscal year that ended in . 20 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: . 20 )	/	EPS without NRI (A: . 20 )
	=		/
	=	N/A

VGI Health Technology's Dividend Payout Ratio for the quarter that ended in . 20 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: . 20 )	/	EPS without NRI (Q: . 20 )
	=		/
	=	N/A

VGI Health Technology (XNEC:VTL) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

VGI Health Technology Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

VGI Health Technology (XNEC:VTL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003

Website

https://www.vgiht.com

VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines